Sommetrics Receives ISO 13485:2016 Certification

Sommetrics, Inc., which provides products to treat airway obstruction during sleep and in acute care settings, announced today that its quality management system has been certified to the rigorous ISO 13485:2016 standard. During the audit process required for certification, Sommetrics was also evaluated and found to be in compliance with the standards of the Medical Device Single Audit Program (MDSAP) for Canada. “This is an important milestone for Sommetrics,” commented Kent Gandola, Vice President of Engineering and Quality Systems. “It reflects the continuing effort of our employees to build a solid foundation for making the transition from a R&D company to one poised for commercial success.”

As a result of the ISO and MDSAP certifications, Sommetrics is now able to apply to HealthCanada for market clearance of the aerSleep® device targeted for the treatment of obstructive sleep apnea (OSA). “These certifications create a number of opportunities for Sommetrics,” said Dr. Richard Rose, President and CEO. “It’s a major step towards taking aerSleep® into global markets where there is a growing need for better-accepted alternative ways of treating OSA, now considered the commonest chronic respiratory disease affecting up to 1 billion people worldwide.”

aerSleep® applies negative pressure to the outside of the upper airway via a soft silicone collar placed over the front of the neck. Since the battery-powered silent vacuum pump is an integral component of the device, no connection to an external vacuum or power source is needed. aerSleep® has been found to be safe and effective in clinical studies with all degrees of OSA severity. In these studies, the majority of people tested found aerSleep® to be preferable to CPAP the most commonly prescribed OSA therapy. Dr. Rose added, “An important advantage of aerSleep® in the COVID-19 era is that it is completely non-invasive. As a result, its use has no risk of generating infectious aerosols which can contaminate the environment – a hazard which has been associated with CPAP use and that can have devastating effects in nursing homes and other care settings.“

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”